课题基金 / 基金详情

The aim of this project is to identify the mechanism of action of factor VII activating protease (FSAP) in vascular diseases and to further develop its diagnostic and therapeutic potential

The aim of this project is to identify the mechanism of action of factor VII activating protease (FSAP) in vascular diseases and to further develop its diagnostic and therapeutic potential
该项目的目的是确定第七因子激活蛋白酶(FSAP)在血管疾病中的作用机制,并进一步开发其诊断和治疗潜力
批准号:
147662156
负责人:
Professor Dr. Sandip M. Kanse, Ph.D.
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2009
资助国家:
德国
项目状态:
已结题
起止时间:
2008-12-31 至 2013-12-31

项目摘要

项目成果

Professor Dr. Sandip M. Kanse, Ph.D.的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Factor VII activating protease (FSAP), a novel plasma protease, has been shown to be linked to vascular diseases in humans since the Marburg I (MI, G534E) polymorphism is a prominent risk factor for atherosclerosis, stroke and venous thromboembolism. We have initiated many studies to investigate the role of this protease in vascular remodelling events such as restenosis, atherosclerosis and pulmonary hypertension. These have been complemented with a) structure function analysis of FSAP and b) the development of FSAP inhibitors. In the applied project we will extend these previous concepts by developing genetic models to investigate the role of FSAP in vivo. These will involve using the FSAP-/- mice and also the modulation of endogenous FSAP expression by using adenoviral expression systems to express FSAP-shRNA or to over-express wild type (WT)- and MI-FSAP. These FSAP-manipulated mice will then be investigated in models of vascular diseases. Furthermore, WT- and MI-FSAP will be over-expressed in bacteria and yeast in therapeutic quantities. These proteins will also be tested in the above described animal models. Moreover, recombinant FSAP proteins will also be used for structure function studies, determination of the substrate specificity and development of specific inhibitors. These investigations will be the basis to define the role of FSAP and the MI-SNP in vascular diseases and will help to realise its therapeutic and diagnostic potential.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1103029
发表时间: 2012-03-15
期刊: JOURNAL OF IMMUNOLOGY
影响因子: 4.4
作者: [Kanse, Sandip M., Gallenmueller, Andrea, Huber-Lang, Markus]
通讯作者: Huber-Lang, Markus
The Factor VII-activating Protease (FSAP) Enhances the Activity of Bone Morphogenetic Protein-2 (BMP-2)*
因子 VII 激活蛋白酶 (FSAP) 增强骨形态发生蛋白 2 (BMP-2) 的活性*
DOI: 10.1074/jbc.m112.433029
发表时间: 2013
期刊: The Journal of Biological Chemistry
影响因子: --
作者: [Roedel EK, Schwarz E, Kanse SM]
通讯作者: Kanse SM
Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP)
缺乏内源性VII因子激活蛋白酶(FSAP)的小鼠中的缺陷性血栓形成
DOI: 10.1160/th14-06-0519
发表时间: 2015
期刊: Thrombosis and Haemostasis
影响因子: 6.7
作者: [Subramaniam S, Thielmann I, Morowski M, Pragst I, Sanset PM, Nieswandt B, Etscheid M, Kanse SM]
通讯作者: Kanse SM
Untersuchungen zur Akkumulation und zum Proliferationsverhalten hämatogener Gefäßmuskelzell-Vorläuferzellen in neointimalem Gewebe
  • 批准号:
    5440203
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2004
  • 负责人:
    Professor Dr. Sandip M. Kanse, Ph.D.
  • 依托单位:
Identification of the molecular mechanisms of signal tranduction via the urokinase-urokinase receptor system and its implications in vascular biology
  • 批准号:
    5235562
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2000
  • 负责人:
    Professor Dr. Sandip M. Kanse, Ph.D.
  • 依托单位:
国内基金
海外基金
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
  • 批准号:
    82370798
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王晓
  • 依托单位:
CD8+T细胞亚群在抗MDA5抗体阳性皮肌炎中的致病机制研究
  • 批准号:
    82371805
  • 项目类别:
    面上项目
  • 资助金额:
    45.00万元
  • 批准年份:
    2023
  • 负责人:
    扶琼
  • 依托单位:
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
  • 批准号:
    82372328
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    项盈
  • 依托单位: